Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') and other regulations, if applicable, we hereby inform the Exchanges that the Board of Directors ('Board') of the Company at its Meeting held on November 09, 2023 has, inter alia, approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended September 30, 2023. The meeting commenced at 12:00 p.m. and concluded at 12:50 p.m.

pdf

Marksans Pharma Ltd.

06 Nov 2023

164.24

-0.48%

Company Update

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Marksans Pharma Limited''s wholly owned subsidiary Relonchem Limited receives market authorization for the product Cyanocobalamin 50mg film coated tablets

pdf

Marksans Pharma Ltd.

03 Nov 2023

164.24

-0.48%

Company Update

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Marksans Pharma Limited hereby announces that its wholly owned subsidiary Time-Cap Laboratories, Inc. has received Establishment Inspection Report (EIR) from USFDA for audit conducted in October 2023.

pdf

Marksans Pharma Ltd.

01 Nov 2023

164.24

-0.48%

Company Update

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Marksans Pharma Limited has scheduled a conference call for analysts and investors on Thursday, November 09, 2023 at 5:30 p.m. (IST) on the unaudited (standalone and consolidated) financial results of the Company for the quarter and half year ended September 30, 2023

pdf

Marksans Pharma Ltd.

01 Nov 2023

164.24

-0.48%

Company Update

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

This is to inform you that Marksans Pharma Limited''s newly acquired manufacturing facility has successfully undergone inspection from German health authorities.

pdf

Marksans Pharma Ltd.

27 Oct 2023

164.24

-0.48%

Board Meeting

MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Prior Intimation Of Board Meeting

BSE India

MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 ,inter alia, to consider and approve To consider and approve the unaudited financial results of the Company (both standalone and consolidated) for the quarter and half year ended September 30, 2023

pdf

Marksans Pharma Ltd.

19 Oct 2023

164.24

-0.48%

Corp. Note

MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / …

BSE India

We have received intimation from our RTA, M/S Big shares services Private Limited today regarding issuance of duplicate share certificate of the Company as per the details attached

pdf

Marksans Pharma Ltd.

12 Oct 2023

164.24

-0.48%

Company Update

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

We wish to inform that CARE Ratings Limited has assigned credit ratings to the banking facilities of Marksans Pharma Limited.

pdf

Is Marksans Pharma Ltd. worth buying?

1424 Votes:

Buy 80.48%

Sell 10.18%

Hold 9.34%